IQV

IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud

Retrieved on: 
Monday, April 8, 2024
Data Management, Biotechnology, Technology, Professional Services, Health, Health Technology, Other Science, Research, Data Analytics, Software, Science, Cloud, CRM, Organization, Partnership, OCE, SVP, Sale, AI, Patient safety, HCP, IQV, Fine chemical

IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.

Key Points: 
  • IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.
  • Building on the IQVIA Orchestrated Customer Engagement ( OCE ) platform, launched in 2017, the partnership will apply innovations from IQVIA OCE with Salesforce’s Life Sciences Cloud to provide customers with a new single, end-to-end engagement platform.
  • As part of the expanded partnership, IQVIA will license the OCE CRM related software to Salesforce, and the parties will collaborate to accelerate development of Life Sciences Cloud for customer engagement, expected to be available in 2025*.
  • “Our collaboration with IQVIA marks a pivotal moment for Salesforce Life Sciences Cloud innovation.

IQVIA CFO Ron Bruehlman to Speak at Barclays Annual Global Healthcare Conference on March 13, 2024

Retrieved on: 
Wednesday, March 6, 2024
Research, Technology, Security, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, IQVIA, Barclays, IQV, Webcast, Conference

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m.
  • ET.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • A replay of the webcast will be available later that day.

IQVIA Publishes its 2023 Environmental, Social and Governance Report

Retrieved on: 
Monday, February 26, 2024
Technology, Pharmaceutical, Health Technology, Environmental, Social and Governance (ESG), Health Insurance, Oncology, Artificial Intelligence, Environment, Research, Medical Devices, Infectious Diseases, Clinical Trials, Environmental Policy, Biotechnology, Professional Services, Health, Recycling, Practice Management, Managed Care, Data Analytics, Science, Climate Change, Sustainability, Data Management, RSV, Woman, Coalition, Investment, Targets, Social, Epidemic, CEPI, ESG, Annual report, Health care, Pharmacy, Patient, Science Based Targets initiative, Plastic, Survival, Lung cancer, Diagnosis, IQV, Workforce, GHG, Public, Management

IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.

Key Points: 
  • IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.
  • “We are proud that we delivered on our sustainability commitments despite the tumultuous macro-environment we have been operating in.”
    IQVIA’s full 2023 ESG report can be downloaded here .
  • We established our dedicated global public health business in 2023, which now works with more than 75 clients across the globe.
  • For the third year in a row, IQVIA was named the number one most admired company in our category, Healthcare: Pharmacy and Other Services.

IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024

Retrieved on: 
Wednesday, February 21, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Other Science, Other Technology, Research, Medical Devices, Software, Health Technology, Science, Data Management, Security, IQVIA, IQV, Webcast

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m.
  • ET.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • A replay of the webcast will be available later that day.

IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance

Retrieved on: 
Wednesday, February 14, 2024
Data Management, Health, Technology, Research, Science, Artificial Intelligence, Biotechnology, DS, Free cash flow, Share repurchase, Growth, ID, Adjustment, RFP, TAS, GAAP, Webcast, COVID, IQV

As of December 31, 2023, R&DS contracted backlog, including reimbursed expenses, was $29.7 billion, growing 9.2 percent year-over-year and 8.8 percent at constant currency.

Key Points: 
  • As of December 31, 2023, R&DS contracted backlog, including reimbursed expenses, was $29.7 billion, growing 9.2 percent year-over-year and 8.8 percent at constant currency.
  • "The IQVIA team delivered solid 2023 results in a challenging macro environment," said Ari Bousbib, chairman and CEO of IQVIA.
  • All financial guidance assumes foreign currency exchange rates as of February 12, 2024 remain in effect for the forecast period.
  • IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its fourth-quarter and full-year 2023 results and 2024 guidance.

IQVIA Named to Fortune® World's Most Admired Companies™ List, Ranked #1 in Its Sector for the Third Consecutive Year

Retrieved on: 
Tuesday, February 6, 2024
Research, Clinical Trials, Professional Services, Other Health, Biotechnology, Data Analytics, Pharmaceutical, Health, Science, Other Science, Social responsibility, IQVIA, Health care, Pharmacy, Korn Ferry, IQV

For the third year in a row IQVIA earned the first-place ranking within the Health Care: Pharmacy and Other Services category.

Key Points: 
  • For the third year in a row IQVIA earned the first-place ranking within the Health Care: Pharmacy and Other Services category.
  • The company also ranked number one in six categories for quality of management, people management, innovation, quality of products and services, global competitiveness, and use of corporate assets.
  • Fortune® World's Most Admired Companies™ is the definitive report card on corporate reputation.
  • Since 1997, Fortune® has identified, selected, and ranked the World’s Most Admired Companies, identifying the business practices that make these companies highly regarded among their peers.

IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024

Retrieved on: 
Wednesday, January 24, 2024
Health Technology, Data Management, Other Health, Technology, Pharmaceutical, Managed Care, Clinical Trials, Other Technology, Science, Biotechnology, Software, Networks, Other Science, Health, Research, IQVIA, ID, IQV, Webcast

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024.
  • The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day.
  • The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com .

IQVIA Digital Enablement Named PM360 Trailblazer 2023 Supplier/Vendor of the Year

Retrieved on: 
Wednesday, November 29, 2023
Technology, Biotechnology, Online Privacy, Health, Pharmaceutical, Professional Services, Medical Devices, Digital Marketing, Advertising, General Health, Data Analytics, Communications, Health Technology, Clinical Trials, Editorial, GM, NYSE, Trailblazer, Social responsibility, IQVIA, Patient, IQV, XR, Advertising agency

IQVIA™ (NYSE:IQV), a leading global provider of data, analytics, technology solutions and services to the life sciences industry, today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category.

Key Points: 
  • IQVIA™ (NYSE:IQV), a leading global provider of data, analytics, technology solutions and services to the life sciences industry, today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category.
  • IQVIA Digital Enablement’s mission is to power exceptional brand experiences.
  • This includes IQVIA’s Audience Identity Manager® XR technology that helps marketers connect with HCPs,” says Anna Stashower, CEO and Publisher of PM360.
  • “We are proud to be recognized by PM360 Trailblazer for our achievements in delivering innovative customer-first solutions, so every customer touchpoint is personalized and leads to better health outcomes,” said Dave Escalante, VP and GM, IQVIA Digital Enablement.

IQVIA CFO Ron Bruehlman to Speak at Evercore HealthCONx Conference on November 29, 2023

Retrieved on: 
Tuesday, November 21, 2023
Software, Research, Pharmaceutical, Data Management, Technology, Security, Health Technology, Online Privacy, Clinical Trials, Science, Biotechnology, Health, Webcast, Information Holdings Inc., IQVIA, NYSE, Conference, IQV, Cryptocurrency, Broadcasting

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on Wednesday, November 29, 2023 at 10:50 a.m.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on Wednesday, November 29, 2023 at 10:50 a.m.
  • ET.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • A replay of the webcast will be available later that day.

IQVIA Announces Upsizing of its Allocation of New Term B Loans

Retrieved on: 
Friday, November 17, 2023
Data Analytics, Health, Data Management, Health Technology, Professional Services, Technology, Online Privacy, Security, Hilltop Holdings Inc., IQVIA, NYSE, IQV, TLB, Security (finance)

IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Borrower”), allocated a new term B loan due 2031 of approximately $1,500 million (the “New Term Loan B”), which was upsized due to lender demand.

Key Points: 
  • IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Borrower”), allocated a new term B loan due 2031 of approximately $1,500 million (the “New Term Loan B”), which was upsized due to lender demand.
  • The proceeds from the New Term Loan B, together with the proceeds from the Borrower’s offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 (the “Notes”), are expected to be used to repay the outstanding Euro-denominated term B loan (“TLB”) due in March 2024, the U.S.-denominated TLB due in January 2025 and the U.S.-denominated TLB due in June 2025 under the Borrower’s senior secured credit facilities, and to pay fees and expenses related to the Borrower’s Notes offering and the Borrower’s credit agreement amendment in respect of the New Term Loan B.
  • In connection with the allocation of the New Term Loan B, the Company entered into a cross-currency swap agreement which will effectively convert the New Term Loan B, upon the closing of such facility, into a euro-denominated borrowing at prevailing euro interest rates to hedge exposure to USD-denominated indebtedness created by the New Term Loan B.
  • The effective net borrowing rate to the Company will be 4.9015%, inclusive of the yield on the New Term Loan B and the beneficial impact of the cross-currency swap.